Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndrome (CMS), or Downbeat Nystagmus Patients (EAP-001)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02189720|
Recruitment Status : Available
First Posted : July 15, 2014
Last Update Posted : February 1, 2017
The primary objective of the study is:
• To provide patients with LEMS/CMS/downbeat nystagmus access to amifampridine phosphate therapy until the product becomes commercially available.
The secondary objective of the study is:
• To assess the long-term safety of amifampridine phosphate in patients with LEMS/CMS/downbeat nystagmus
|Condition or disease||Intervention/treatment|
|Lambert-Eaton Myasthenic Syndrome Congenital Myasthenic Syndrome Downbeat Nystagmus||Drug: Amifampridine Phosphate|
|Study Type :||Expanded Access|
|Official Title:||An Open-Label, Expanded Access Protocol for Amifampridine Phosphate Treatment in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndrome (CMS) and Downbeat Nystagmus|
Drug: Amifampridine Phosphate
- 3,4-Diaminopyridine Phosphate
- 3,4 DAP
Dosage form: tablets containing the equivalent of 10 mg amifampridine base per tablet.
Amifampridine Phosphate is taken with food and each patient is given an individualized dose based on Investigator assessment of optimal neuromuscular benefit. Doses range from 30 mg to 80 mg, divided into doses taken 3 to 4 times per day, with a maximum single dose of 20 mg.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02189720
|Contact: Jonathan Rubine, MD||305-420-3200 ext firstname.lastname@example.org|
|United States, California|
|Los Angeles, California, United States, 90095|
|Contact: Clara Sam 310-825-3264 email@example.com|
|Contact: Gary Ingenito, MD, PhD 305-420-3200 ext 123 firstname.lastname@example.org|
|Principal Investigator:||Perry Shieh, MD, PhD||University of California, Los Angeles|